



PRESS RELEASE

Published: 14-09-2018

Inhalation Sciences' subsidiary Ziccum announces approval for listing on Spotlight.

STOCKHOLM, SWEDEN – 14 September, 2018. Inhalation Sciences subsidiary Ziccum has been approved for listing on Stockholm stock market Spotlight, provided that the minimum limit of the company's new issue and the marketplace's proprietary spread requirements are met. The subscription period for the company's new share issue will begin on September 19 and continue until October 3, 2018. The first day of trading on Spotlight is scheduled for October 25, 2018.

The new issue will take place with preference for Inhalation Sciences' shareholders. Shareholders in Ziccum receive a unit right for each held share. A unit right entitles you to subscribe to a unit consisting of one share and one subscription option, in Ziccum.

Shareholders in Inhalation Sciences are offered priority subscription in the listing issue, through Inhalation Sciences distributing their unit rights. For every four shares in Inhalation Sciences, one unit right is obtained in Ziccum. The last day for trading in Inhalation Sciences shares, including the right to unit rights, will be September 12, 2018.

More detailed descriptions of Ziccum, its Investment Memorandum, Teaser and Application Form will be available on the companies' respective websites, www.ziccum.com and www.spotlightstockmarket.com by latest 18 September.

"Approval from Spotlight is an important step forward towards Ziccum standing on its own two feet," says ISAB CEO Lena Heffler. "We're pleased we've been able to keep to the timetable communicated on our listing, and to offer our owners priority in Ziccum's listing issue."

For more information on Inhalation Sciences please contact:

Lena Heffler, CEO

Email: lena.heffler@inhalation.se

Mob: +46 (0)70 205 9620

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company's patented lab instrument,

Preciselnhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.

For more information on Ziccum, please contact:

Göran Conradson: CEO

Email: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum AB

Ziccum AB develops and commercializes the patented spray-drying instrument LaminarPace®. LaminarPace is an innovative, CE-labelled instrument that dries small amounts of drug substances with very low losses. The vast majority of pharmaceutical projects prefer substances in dry powder form, as it increases their stability, durability and simplifies logistics and transportation. LaminarPace is also unique in its ability to handle temperature-sensitive materials such as proteins and peptides.